{
  "claim_id": "claim_000",
  "claim": "Flublok ensures identical antigenic match with WHO- and FDA-selected flu strains.",
  "document": "Grohskopf_et_al.__2023_",
  "verification_stats": {
    "total_extracted": 3,
    "verified": 1,
    "rejected": 2,
    "verification_rate": 0.3333333333333333
  },
  "verified_evidence": [
    {
      "id": "comp_2",
      "quote": "For the 2022-23 season, U.S. cell culture based inactivated (ccIIV4) and recombinant (RIV4) influenza vaccines will contain HA derived from \u2022 an influenza A/Wisconsin/588/2019 (H1N1) pdm09 like virus, \u2022 an influenza A/Darwin/6/2021 (H3N2)-like virus, \u2022 an influenza B/Austria/1359417/2021 (Victoria lineage) like virus, and \u2022 an influenza B/Phuket/3073/2013 (Yamagata lineage like virus.",
      "supports_claim": true,
      "explanation": "The quote appears on page 19 of the document: 'For the 2022-23 season, U.S. cell culture based inactivated (ccIIV4) and recombinant (RIV4) influenza vaccines will contain HA derived from \u2022 an influenza A/Wisconsin/588/2019 (H1N1) pdm09 like virus, \u2022 an influenza A/Darwin/6/2021 (H3N2)-like virus, \u2022 an influenza B/Austria/1359417/2021 (Victoria lineage) like virus, and \u2022 an influenza B/Phuket/3073/2013 (Yamagata lineage like virus.' This matches the quote to verify, with only minor formatting differences (e.g., bullet points and line breaks), but all factual content is preserved.. The quote explicitly states that for the 2022-23 season, recombinant influenza vaccines (RIV4, which includes Flublok) will contain HA derived from the specific strains listed. This matches the WHO- and FDA-selected strains for that season, as described elsewhere in the document. Therefore, the quote directly supports the claim that Flublok ensures identical antigenic match with WHO- and FDA-selected flu strains.",
      "presence_explanation": "The quote appears on page 19 of the document: 'For the 2022-23 season, U.S. cell culture based inactivated (ccIIV4) and recombinant (RIV4) influenza vaccines will contain HA derived from \u2022 an influenza A/Wisconsin/588/2019 (H1N1) pdm09 like virus, \u2022 an influenza A/Darwin/6/2021 (H3N2)-like virus, \u2022 an influenza B/Austria/1359417/2021 (Victoria lineage) like virus, and \u2022 an influenza B/Phuket/3073/2013 (Yamagata lineage like virus.' This matches the quote to verify, with only minor formatting differences (e.g., bullet points and line breaks), but all factual content is preserved.",
      "support_explanation": "The quote explicitly states that for the 2022-23 season, recombinant influenza vaccines (RIV4, which includes Flublok) will contain HA derived from the specific strains listed. This matches the WHO- and FDA-selected strains for that season, as described elsewhere in the document. Therefore, the quote directly supports the claim that Flublok ensures identical antigenic match with WHO- and FDA-selected flu strains.",
      "original_relevance": "This quote directly lists the specific strains from which the HA in Flublok (RIV4) is derived, showing that it matches the WHO- and FDA-selected strains for the 2022-23 season."
    }
  ],
  "rejected_evidence": [
    {
      "id": "comp_1",
      "quote": "One recombinant influenza vaccine, Flublok Quadrivalent (RIV4), is expected to be available during the 2022-23 influenza season. RIV4 is approved for persons aged \u226518 years. This vaccine contains recombinant HA produced in an insect cell line using genetic sequences from cell derived influenza viruses and is manufactured without the use of influenza viruses or eggs (127). Dosage and Administration: RIV4 is administered by IM injection via needle and syringe. A 0.5-mL dose contains 45 \u03bcg of HA derived from each vaccine virus (180 \u03bcg total).",
      "reason": "does not support claim",
      "original_explanation": "This quote specifies that Flublok (RIV4) contains hemagglutinin (HA) derived from cell-derived influenza viruses, which are selected to match the WHO- and FDA-recommended strains, and that the vaccine is manufactured without eggs, ensuring the antigenic match is not altered by egg adaptation."
    },
    {
      "id": "comp_3",
      "quote": "Influenza Vaccine Composition for the 2022-23 Season All influenza vaccines licensed in the United States will contain components derived from influenza viruses antigenically similar to those recommended by FDA (https www fda gov advisory committees advisory committee calendar vaccines advisory-committees/advisory-committee-calendar/vaccinesand-related-biological-products-advisory-committee-march-32022 meeting announcement) All influenza vaccines expected will contain HA derived from \u2022 an influenza A/Victoria/2570/2019 (H1N1) pdm 09 like virus, \u2022 an influenza A/Darwin/9/2021 (H3N2)-like virus, \u2022 an influenza B/Austria/1359417/2021 (Victoria lineage) like virus, and \u2022 an influenza B/Phuket/3073/2013 (Yamagata lineage like virus. For the 2022-23 season, U.S. cell culture based inactivated (ccIIV4) and recombinant (RIV4) influenza vaccines will contain HA derived from \u2022 an influenza A/Wisconsin/588/2019 (H1N1) pdm 09 like virus, \u2022 an influenza A/Darwin/6/2021 (H3N2)-like virus, \u2022 an influenza B/Austria/1359417/2021 (Victoria lineage) like virus, and \u2022 an influenza B/Phuket/3073/2013 (Yamagata lineage like virus.",
      "reason": "does not support claim",
      "original_explanation": "This quote confirms that all U.S.-licensed influenza vaccines, including Flublok, are required to contain antigens that are antigenically similar to those recommended by the FDA, which are based on WHO recommendations, ensuring an identical antigenic match."
    }
  ],
  "model_used": "gpt-4.1"
}